RACHEL COLE: Open Payments
NPI 1104348358 · HOPKINSVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$126,777 in 296 payments from 10 companies in 2025. Trend: 2023 $136,772 · 2024 $115,842 · 2025 $126,777
Speaker / faculty: $109,205Travel & lodging: $10,212Consulting: $3,720Food & beverage: $3,640
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 198 | $105,016 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $20,722 |
| E.R. Squibb & Sons, L.L.C. | 21 | $367 |
| Neurocrine BioSciences, Inc. | 13 | $165 |
| Vanda Pharmaceuticals Inc. | 7 | $153 |
| Alkermes, Inc. | 10 | $135 |
| Janssen Pharmaceuticals, Inc | 4 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
Products named: VRAYLAR, CAPLYTA, COBENFY, INGREZZA, ARISTADA, FANAPT, INVEGA SUSTENNA, UZEDY.
Industry payments across KY — which companies pay providers there.
